Publications by authors named "Lidia Ksiazek"
Invest New Drugs
October 2017
Article Synopsis
- - Docetaxel and prednisolone chemotherapy (DP) improves survival in metastatic castration-resistant prostate cancer (mCRPC), but resistance often develops due to AKT pathway activation.
- - A phase I trial was conducted to find the best dose of AZD5363, a potent AKT inhibitor that may work well with DP, in chemotherapy-naive mCRPC patients.
- - The trial involved 10 patients, identifying 320 mg as the recommended dose for AZD5363 alongside full dose DP, with some side effects like rash and diarrhea reported.
